Key clinical point: A triple-antiviral combination was effective at treating mild to moderate COVID-19 infections.
Major finding: Median time to viral negativity was 7 days with lopinavir/ritonavir, interferon, and ribavirin vs. 12 days with lopinavir/ritonavir alone.
Study details: Randomized phase 2 trial in 127 patients hospitalized with COVID-19.
Disclosures: The study was funded by the Shaw Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine. The authors and Dr. Medoff declared no competing interests.
Hung IFN et al. Lancet. 2020 May 8. doi: 10.1016/S0140-6736(20)31101-6.